Sellas Life Sciences announced top-line data from the Phase 2 clinical study of its WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM).
The Phase 2 double-blind, randomized study compared WT-1 analog peptides vaccine in combination with Montanide-adjuvant plus granulocyte-macrophage colony-stimulating factor (GM-CSF) vs. Montanide-adjuvant plus GM-CSF in patients with MPM who had previously completed combined modality therapy. The study planned to enroll 39 patients in each arm, however, in May 2015, the trial’s independent Data Monitoring Committee requested discontinuation of the control arm due to futility while continuing the WT1 cancer vaccine arm. This change led to an earlier unblinding than planned, with total enrollment reaching 40 patients, 19 in the WT1 vaccine arm and 21 in the control arm.
[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.